171 related articles for article (PubMed ID: 22085894)
1. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma.
Leitao MM; Hensley ML; Barakat RR; Aghajanian C; Gardner GJ; Jewell EL; O'Cearbhaill R; Soslow RA
Gynecol Oncol; 2012 Mar; 124(3):558-62. PubMed ID: 22085894
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
3. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
4. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE; Yavuz E; Tecer A; Iyibozkurt CA; Topuz S; Tuzlali S; Bengisu E; Berkman S
Gynecol Oncol; 2005 Oct; 99(1):36-42. PubMed ID: 15992918
[TBL] [Abstract][Full Text] [Related]
5. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
[TBL] [Abstract][Full Text] [Related]
6. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
8. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.
Mittal K; Joutovsky A
Gynecol Oncol; 2007 Feb; 104(2):362-5. PubMed ID: 17011615
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients.
Yang XY; Xi MR; Yang KX; Yu H
Gynecol Oncol; 2009 Apr; 113(1):99-104. PubMed ID: 19178934
[TBL] [Abstract][Full Text] [Related]
10. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
George S; Feng Y; Manola J; Nucci MR; Butrynski JE; Morgan JA; Ramaiya N; Quek R; Penson RT; Wagner AJ; Harmon D; Demetri GD; Krasner C
Cancer; 2014 Mar; 120(5):738-43. PubMed ID: 24222211
[TBL] [Abstract][Full Text] [Related]
13. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
19. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
20. Cluster analysis of immunohistochemical markers in leiomyosarcoma delineates specific anatomic and gender subgroups.
Carvalho JC; Thomas DG; Lucas DR
Cancer; 2009 Sep; 115(18):4186-95. PubMed ID: 19626649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]